Next-generation commercial data warehouse speeds implementation and
automatically syncs with most important data sources
PLEASANTON, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/cloud?src=hash" target="_blank"gt;#cloudlt;/agt;–Veeva
Systems (NYSE:VEEV) today announced that life sciences companies are
adopting Veeva
Nitro to accelerate their data warehouse projects and deliver faster
insights to the business. Veeva Nitro is a life sciences-specific
commercial data warehouse that eliminates the time and effort of custom
data warehouses and provides a foundation for artificial intelligence
(AI) and advanced analytics. In half a year since the product’s
availability, six companies have selected Veeva Nitro, including
Karyopharm Therapeutics (NASDAQ:KPTI) and MannKind Corporation
(NASDAQ:MNKD), with both customers live and using the product in under
five months.
With a fast-growing oncology business and a new therapy coming to
market, Karyopharm Therapeutics needed to bring together a variety of
data sets – including Veeva
CRM and claims data – to empower field teams with the right
information to reach the right stakeholders.
“Veeva Nitro removed many of the challenges in implementing a data
warehouse and accelerated our ability to provide the field with useful,
actionable insights,” said Jason Magyar, sr. director, enterprise
applications, Karyopharm Therapeutics. “In just a few months, we gained
a host of capabilities with Veeva
Commercial Cloud and Veeva Nitro that other solutions sometimes take
years to deliver, if ever. We now have a solid foundation for growth and
to drive intelligent customer engagement.”
Veeva Nitro provides an industry-specific data model and standard
integrations that unify a company’s most important data sources,
including prescription, sales, formulary, and claims data. Data is
automatically updated when data structures or sources change,
eliminating the significant effort typically required to maintain a
custom-built data warehouse.
Analytics-ready, Veeva Nitro also gives companies the flexibility to use
the business intelligence and AI tools of their choice. With seamless
integration to Veeva
CRM MyInsights, any time data changes in Veeva Nitro it
automatically syncs in Veeva CRM MyInsights. Now customers can deliver
tailored insights to field teams right at the point of execution on any
mobile device.
“Veeva Nitro allowed us to build and configure our data warehouse
quickly and efficiently,” said Andrew Zepfel, associate director, sales
operations, MannKind Corporation, a biopharmaceutical company that
provides therapeutic products for patients with diseases such as
diabetes. “Veeva Nitro will allow us to keep up with changes in the
business as they happen and give us a foundation for advanced analytics.”
“For decades the life sciences industry has been held back by custom
data warehouses that are inflexible and out-of-date, so they fail to
deliver the right insights to the business,” said Andy Fuchs, vice
president, Veeva Nitro. “Veeva Nitro finally gives companies a pre-built
commercial data warehouse that is fast to deploy and delivers always
current insights at speeds that were never before possible.”
Veeva Nitro is available today in North America and Japan and planned
for availability in Europe in mid-2019.
Learn more about Veeva Nitro at the upcoming Veeva Commercial & Medical
Summit, May 13-15 in Philadelphia, PA. The event is open to Veeva
customers and invited guests. Register and view the agenda at veeva.com/Summit.
Additional Information
For more on Veeva Nitro, visit: veeva.com/Nitro
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in
cloud-based software for the global life sciences industry. Committed to
innovation, product excellence, and customer success, Veeva has more
than 700 customers, ranging from the world’s largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices throughout North America, Europe, Asia,
and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains
forward-looking statements, including the market demand for and
acceptance of Veeva’s products and services, the results from use of
Veeva’s products and services, and general business conditions,
particularly in the life sciences industry. Any forward-looking
statements contained in this press release are based upon Veeva’s
historical performance and its current plans, estimates, and
expectations, and are not a representation that such plans, estimates,
or expectations will be achieved. These forward-looking statements
represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-Q for the period ended October 31, 2018. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
Contacts
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Lisa Barbadora
Veeva Systems
610-420-3413
pr@veeva.com